Issue link: https://www.e-digitaleditions.com/i/1138630
Acid Resistant Vegetable Capsules ) u . u, ' . AN EXCELLENT CHOICE FOR DELIVERY OF ACID-SENSITIVE ACTIVE INGREDIENTS . <> . BioCaps Enterprises, Inc. www.biocaps.net • info@biocaps.net US Patent 9452141 5. M. F. Brin and D. S. Younger. "Neurologic disorders and aspiration." Otolaryngolic Clinics of North America. 1988. Vol. 21, pages 691-699. 6. K. A. Layne, D. S. Losinski, P. M. Zenner, and J. A. Ament. "Using the Fleming index of dysphagia to estab- lish prevalence." Dysphagia. 1989. Vol. 4, pages 39-42. 7. Felipe L. Lopez, Terry B. Ernest, Catherine Tuleu and Mine Orlu Gul. "Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms." Expert Opinion on Drug Delivery. 2015. Vol. 12, No. 11, pages 1,727-1,740. 8. M. A. Frohoff-Hulsmann, A. Schmitz, and B. C. Lippold, "Aqueous ethyl cellulose dispersions containing plasticizers of different water solubility and hydroxypro- pyl methylcellulose as coating material for diffusion pel- lets. I. Drug release rates from coated pellets." International Journal of Pharmaceutics. 1999. Vol. 177, No. 1, pages 69-82. Sreeramaiah Arunkumar is formulation & development scientist, technology & innovation, India; Michael Baumann is global strategic marketing manager, immediate release pharmaceutical dosage forms; Rina Chokshi is global leader for regional and field marketing; and Vinay Muley is leader, pharmaceutical excipi- ents, technology & innovation, India, for DuPont Nutrition & Biosciences. For questions or comments about this article, please contact Lindsay Torriero, brand & global content leader, DuPont Nutrition & Biosciences (lindsay.torriero@dupont.com). all the tablets was within acceptable limits of pharmaco- poeia standards. Overall, the coated particles saw improved flow characteristics and compaction properties. When the model tablets were tested for in-process quality control and taste-masking performance, the researchers found that both the mouthfeel and disintegra- tion time were acceptable to patients. Researchers noted that such characteristics could be improved by optimiz- ing the coating parameters and ODT formulation design. By optimizing the parameters, manufacturers can ensure better product development, including efficient perfor- mance of ODTs with required taste-masking ability. The model formulation shows that, by using ECD in fluidized-bed processor coating, drug product manufactur- ers can provide patient-friendly ODTs with a pleasant mouthfeel and good taste-masking qualities. This has the potential to both increase patient adherence and broaden the possibilities of APIs suitable for ODT formulation. T&C References 1. S. R. Barczi, P.A. Sullivan, and J. Robbins. "How should dysphagia care of older adults differ? Establishing optimal practice patterns." Seminars in Speech and Language. 2000. Vol. 21, No. 4, pages 347-361. 2. H. Siebens, E. Trupe, A. Siebens, et al. "Correlates and consequences of eating dependency in institutional- ized elderly." Journal of the American Geriatrics Society. 1986. Vol. 34, No. 3, pages 192-198. 3. L. I. Black, A. Vahratian, and H. J. Hoffman. "Communication disorders and use of intervention ser- vices among children aged 3-17 years: United States, 2012." NHS Data Brief. 2015. No. 205. Hyattsville, MD: National Center for Health Statistics. 4. "Global market study on orally disintegrating tab- lets: Anti-psychotics drug class segment to record market attractiveness index of 2.4 over the forecast period 2017 – 2025." Persistence Market Research. August 2017. Figure 4 In vitro dissolution profile of test ODT formulation versus commercial formulation API release (%) 100 80 60 40 20 0 0 10 20 30 40 50 Time (minutes) Test paracetamol ODT Marketed paracetamol ODT Tablets & Capsules July 2019 27